App-Quantinova.ai

Standardizing the analysis of spatial imaging features in tumor samples

Jason Weirather - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Real-world treatment patterns and clinical outcomes in patients with metastatic NSCLC after receiving first-line pembrolizumab with pemetrexed/platinum chemotherapy in the US oncology network

Jerome Goldschmidt - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

Prognostic value of natural killer cell activity and derived neutrophils-to-lymphocytes ratio in non-small cell lung cancer patients receiving immune checkpoint inhibitors

Line Nederby - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Interferon Gamma

Multispectral Immunohistochemistry reveals an immunosuppressive tumour microenvironment in esophageal adenocarcinoma

Charles Rayner - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Significantly different immune microenvironment between triple-negative breast cancer with and without neoadjuvant chemotherapy through multiplex immunohistochemistry

Miseon Lee - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

IL-27 expressed in the tumor microenvironment is correlated with PD-L1 levels and can induce PD-L1 expression on immune and tumor cells

Karin Golan - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Interleukin

Effect of sub-ablative hyperthermia on PD-1/PD-L1 axis modulation in the tumor microenvironment

Md Raihan Chowdhury - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Breast cancer

N/A

Epigenetic modifications influence immune regulatory pathways in murine and human neuroblastoma and melanoma tumor models

Arika Feils - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

N/A

Costimulatory CD28 trispecific antibodies targeting PDL1 and PDL2 enhance T cell activation in solid tumors

Veronica Zeng - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interferon Gamma

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events

David Kozono - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pancreatitis

N/A

CT scan normalization to improve radiomics generalizability and assess progression-free survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study

Marion Tonneau - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Predicting response to immune checkpoint inhibitors (ICI) in non-small-cell lung cancer (NSCLC) by combining spatial analysis of cells and RNA sequencing data from biopsies using deep learning (DL)

Ettai Markovits - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Radiomics and delta-radiomics signatures to predict response and survival in patient with non-small cell lung cancer treated with immune checkpoint inhibitors

Francois Cousin - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Novel gut-restricted small molecule inhibitor of PD-L1 for targeting GI cancers

Dhanalakshmi Sivanandhan - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Novel, brain penetrant small molecule inhibitor of PD-L1 for targeting glioblastoma and brain metastasis

Dhanalakshmi Sivanandhan - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

Trilaciclib, an intravenous cyclin-dependent kinase 4/6 inhibitor, enhances antitumor responses by modulating T cells

Sarah Ahn - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

G1T28-1

A bifunctional tumor activated immunomodulator (TRACIr) targeting PD-L1 And CD28 Is a potent enhancer of T cell-mediated anti-tumor activity

Thomas DiRaimondo - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

TGN1412

Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC

Charu Aggarwal - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Racial ethnic differences in treatment of advanced non-small cell lung cancer with immune checkpoint inhibitors: analysis of a large real-world dataset

Laura Oswald - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Risk factors for hyperprogressive disease in lung cancer patients using two different definitions

Trie Arni Djunadi - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Filters

4177 Abstracts